8-K: Palisade Bio Advances PALI-2108 to Phase 2, Reports Q2 2026 Results

Palisade Bio announced second quarter 2026 financial results, highlighting the advancement of its lead drug candidate PALI-2108 into Phase 2 development for inflammatory bowel disease and a strong cash position.

Summary

• Palisade Bio reported its financial results for the second quarter ended June 30, 2026.
• The company is advancing its lead drug candidate, PALI-2108, into Phase 2 development for ulcerative colitis (UC) and Crohn's disease (CD).
• Enrollment for the Phase 2 ASCENTRA-UC trial is expected in the second half of 2026, with primary efficacy results anticipated in the second half of 2027.
• An Investigational New Drug (IND) application for the Phase 2 ASCENTRA-CD trial is expected in the second half of 2026, with primary efficacy results expected in early 2028.
• Phase 1 trial results for PALI-2108 showed favorable safety, tolerability, and targeted distribution, with positive clinical response and remission rates in UC patients and significant reduction in SES-CD scores in fibrostenotic Crohn's disease patients.
• Research and development expenses increased significantly to $7.4 million for Q2 2026 from $1.7 million in Q2 2025, driven by clinical operations and CMC activities.
• General and administrative expenses also rose to $4.8 million for Q2 2026 from $1.2 million in Q2 2025, attributed to employee-related costs and professional fees.
• The company reported license revenue of $0.5 million for Q2 2026 related to a milestone with Newsoara.
• Net loss for Q2 2026 was $10.6 million ($0.05 per share), compared to $2.8 million ($0.58 per share) in Q2 2025.
• As of June 30, 2026, the company had $125.2 million in cash and cash equivalents, sufficient to fund operations through major clinical development milestones.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, with significant progress in clinical trials and a strong cash position, balanced by increased operating expenses and a widening net loss.

Positives

• PALI-2108 demonstrated favorable safety and tolerability in Phase 1 trials.
• Phase 1 UC cohort showed 5 out of 5 patients achieving clinical response and 2 out of 5 achieving clinical remission.
• PALI-2108 reduced mean SES-CD score by approximately 47.5% in fibrostenotic Crohn's disease patients.
• IND clearance received for the Phase 2 ASCENTRA-UC trial.
• Enrollment for Phase 2 ASCENTRA-UC trial expected in the second half of 2026.
• IND submission for Phase 2 ASCENTRA-CD trial expected in the second half of 2026.
• Strong balance sheet with $125.2 million in cash and cash equivalents as of June 30, 2026, expected to support operations through key Phase 2 milestones.
• Strengthened the Board of Directors with two industry veterans.

Negatives

• Research and development expenses increased by over 300% to $7.4 million in Q2 2026 compared to Q2 2025.
• General and administrative expenses increased by nearly 300% to $4.8 million in Q2 2026 compared to Q2 2025.
• Net loss widened significantly to $10.6 million in Q2 2026 from $2.8 million in Q2 2025.
• Basic and diluted net loss per common share increased from $0.58 in Q2 2025 to $0.05 in Q2 2026, reflecting a higher number of outstanding shares.
• The company's cash and cash equivalents decreased from $133.4 million at the beginning of the year to $125.2 million at the end of Q2 2026.

Risks

• The risk that prior Phase 1 results, such as signals of safety, clinical response, efficacy, or durability of effect, observed in a limited number of patients, will not be replicated or will not continue in ongoing or future studies.
• The company's reliance on PALI-2108 and its early stage of clinical development.
• The timing of enrollment, commencement, and completion of clinical trials.
• Potential for adverse events or unexpected safety findings in Phase 2 trials.
• Competition from existing and emerging therapies for inflammatory bowel disease.
• The company's ability to manage increased operating expenses as it advances clinical development.
• The risk that the company's cash runway may not be sufficient to reach all anticipated milestones if development timelines are extended or costs increase.

Future Outlook

The company expects to commence the Phase 2 ASCENTRA-UC trial in the second half of 2026 and submit an IND for the Phase 2 ASCENTRA-CD trial in the second half of 2026. Primary efficacy readouts are anticipated in the second half of 2027 for UC and early 2028 for CD. The company believes its current cash resources are sufficient to fund operations through these major clinical development milestones.

Management Comments

• "The second quarter marked a decisive transition for Palisade Bio as we completed the regulatory and operational work required to advance PALI-2108 into Phase 2 development," said JD Finley, Chief Executive Officer of Palisade Bio.
• "With FDA clearance of our IND, encouraging Phase 1 results and a strong financial position, we expect to commence the Phase 2 ASCENTRA-UC trial in the second half of 2026."
• "PALI-2108 was engineered for targeted activation within the gastrointestinal tract, with the goal of delivering sustained PDE4 inhibition while improving tolerability and convenience."
• "We believe the ASCENTRA-UC Phase 2 trial represents a significant opportunity to demonstrate that differentiated profile in a larger patient population and establish PALI-2108 as a potentially best-in-class, once-daily oral therapy for IBD."
• "Crohns disease is a core component of the PALI-2108 clinical development program and is advancing in parallel with ASCENTRA-UC. We believe that PALI-2108s targeted activation and localized delivery in both the ileum and colon are particularly relevant to Crohns disease, which can affect multiple regions of the gastrointestinal tract.", added Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio.
• "We are finalizing the design of the Phase 2 ASCENTRA-CD trial and expect to submit an IND in the second half of 2026."
• "With active programs in both Crohns disease and ulcerative colitis, PALI-2108 is positioned to address the two largest indications within IBD."

Industry Context

StockSavvy.ai notes that Palisade Bio's progress with PALI-2108 aligns with the ongoing industry trend of developing targeted therapies for inflammatory bowel disease (IBD) that aim to improve efficacy and reduce side effects compared to existing treatments. The focus on PDE4 inhibition and localized activation addresses unmet needs in a market where many patients do not achieve durable remission.

Comparison to Industry Standards

• The Phase 1 results for PALI-2108, showing clinical response and remission rates in UC patients and significant SES-CD score reduction in fibrostenotic Crohn's disease patients, are encouraging and provide a basis for comparison with other IBD therapies.
• Companies like Takeda (with its JAK inhibitor, vedolizumab) and AbbVie (with its JAK inhibitor, upadacitinib) are also developing advanced therapies for IBD, but PALI-2108's proposed mechanism of targeted PDE4 inhibition and oral administration offers a potentially differentiated profile.
• The reported Phase 1 safety and tolerability profile, along with sustained exposure of the active metabolite above IC90, are key benchmarks for advancing into Phase 2 development, where larger patient populations will be evaluated.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from advancement of PALI-2108 into Phase 2 trials and strong cash position, but also potential dilution concerns if future capital raises are needed. Increased operating expenses and net loss may be a concern.
• Patients: Potential for a new, more effective, and convenient oral treatment option for inflammatory bowel disease (IBD) if PALI-2108 proves successful in clinical trials.
• Employees: Increased R&D and G&A expenses suggest continued investment in personnel and operations, potentially leading to growth.
• Creditors: The company's strong cash position provides a buffer for its financial obligations.

Next Steps

• Enrollment of the first patient for the Phase 2 ASCENTRA-UC trial in the second half of 2026.
• Submission of the IND application for the Phase 2 ASCENTRA-CD trial in the second half of 2026.
• Commencement of the Phase 2 ASCENTRA-CD clinical trial targeted for the first quarter of 2027.
• Presentation of additional PALI-2108 data at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and United European Gastroenterology (UEG) Week 2026.
• Achieve primary efficacy readout from the Phase 2 ASCENTRA-UC trial in the second half of 2027.
• Achieve primary efficacy readout from the Phase 2 ASCENTRA-CD trial in early 2028.

Key Dates

Recommendation

The company is making significant progress in its clinical development pipeline with PALI-2108 advancing to Phase 2, supported by encouraging Phase 1 data and a strong cash position. However, the substantial increase in operating expenses and widening net loss, coupled with the early stage of development and inherent risks in clinical trials, warrant a cautious 'hold' rating. Investors should monitor upcoming Phase 2 trial results closely.

Keywords

PALI-2108, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, PDE4 inhibitor, Phase 2 Trial, Biopharmaceutical, Clinical Development